PubMed

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration.

Hurley SF, Matthews JP, Guymer RH.

Cost Eff Resour Alloc. 2008 Jun 24;6:12.PMID: 18573218 [PubMed - in process]Related articlesFree article

Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.

Hernández-Pastor LJ, Ortega A, García-Layana A, Giráldez J.

Graefes Arch Clin Exp Ophthalmol. 2010 Apr;248(4):467-76. Epub 2009 Aug 11.PMID: 19669678 [PubMed - in process]Related articles

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.

Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.

Clin Ther. 2008 Dec;30(12):2436-51.PMID: 19167602 [PubMed - indexed for MEDLINE]Related articles

A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.

Brown MM, Brown GC, Brown HC, Peet J.

Ophthalmology. 2008 Jun;115(6):1039-1045.e5. Epub 2007 Nov 5.PMID: 17976724 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of smoking cessation to prevent age-related macular degeneration.

Hurley SF, Matthews JP, Guymer RH.

Cost Eff Resour Alloc. 2008 Sep 11;6:18.PMID: 18783631 [PubMed - in process]Related articlesFree article

Computerized model of cost-utility analysis for treatment of age-related macular degeneration.

Fletcher EC, Lade RJ, Adewoyin T, Chong NV.

Ophthalmology. 2008 Dec;115(12):2192-8. Epub 2008 Oct 18.PMID: 18930556 [PubMed - indexed for MEDLINE]Related articles

[Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration]

Neubauer AS, Holz FG, Schrader W, Back EI, Kühn T, Hirneiss C, Kampik A.

Klin Monbl Augenheilkd. 2007 Sep;224(9):727-32. German. PMID: 17846963 [PubMed - indexed for MEDLINE]Related articles

The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.

Rein DB, Wittenborn JS, Lee PP, Wirth KE, Sorensen SW, Hoerger TJ, Saaddine JB.

Ophthalmology. 2009 May;116(5):823-32. Epub 2009 Mar 14.PMID: 19285730 [PubMed - indexed for MEDLINE]Related articles

The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration.

Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S.

Trans Am Ophthalmol Soc. 2007;105:160-9; discussion 169-71.PMID: 18427606 [PubMed - indexed for MEDLINE]Related articlesFree article

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness.

Raftery J, Clegg A, Jones J, Tan SC, Lotery A.

Br J Ophthalmol. 2007 Sep;91(9):1244-6. Epub 2007 Apr 12.PMID: 17431015 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration.

Cohen SY, Bremond-Gignac D, Quentel G, Mimoun G, Citterio T, Bisot-Locard S, Beresniak A.

Graefes Arch Clin Exp Ophthalmol. 2008 Nov;246(11):1527-34. Epub 2008 Jul 19.PMID: 18642019 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.

Javitt JC, Zlateva GP, Earnshaw SR, Pleil AM, Graham CN, Brogan AJ, Shah SN, Adamis AP.

Value Health. 2008 Jul-Aug;11(4):563-74. Epub 2007 Dec 17.PMID: 18179676 [PubMed - indexed for MEDLINE]Related articles

Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations.

Grieve R, Guerriero C, Walker J, Tomlin K, Langham J, Harding S, Chakravathy U, Carpenter J, Reeves BC; Verteporfin Photodynamic Therapy Cohort Study Group.

Ophthalmology. 2009 Dec;116(12):2471-77.e1-2.PMID: 19948278 [PubMed - indexed for MEDLINE]Related articles

The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.

Roe RH, Lass JH, Brown GC, Brown MM.

Cornea. 2008 Oct;27(9):1001-7.PMID: 18812762 [PubMed - indexed for MEDLINE]Related articles

A cost-effectiveness analysis of three treatments for age-related macular degeneration.

Gower EW, Cassard SD, Bass EB, Schein OD, Bressler NM.

Retina. 2010 Feb;30(2):212-21.PMID: 19940805 [PubMed - in process]Related articles

Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule.

Milne RJ, Grimwood K.

Value Health. 2009 Sep;12(6):888-98. Epub 2009 Mar 18.PMID: 19490550 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of vitamin therapy for age-related macular degeneration.

Rein DB, Saaddine JB, Wittenborn JS, Wirth KE, Hoerger TJ, Narayan KM, Clemons T, Sorensen SW.

Ophthalmology. 2007 Jul;114(7):1319-26. Epub 2007 Feb 22.PMID: 17320962 [PubMed - indexed for MEDLINE]Related articles

Economic implications of current age-related macular degeneration treatments.

Smiddy WE.

Ophthalmology. 2009 Mar;116(3):481-7. Epub 2009 Jan 20.PMID: 19157562 [PubMed - indexed for MEDLINE]Related articles

Combination photodynamic therapy and intravitreal ranibizumab in neovascular age-related macular degeneration in a North Indian population: a pilot study.

Kumar A, Gopalakrishnan K, Sinha S.

Retina. 2008 Oct;28(9):1296-301.PMID: 18667951 [PubMed - indexed for MEDLINE]Related articles

Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.

Stepien KE, Rosenfeld PJ, Puliafito CA, Feuer W, Shi W, Al-Attar L, Dubovy SR, Murray TG, Davis JL, Lee WH, Schwartz SG, Smiddy WE, Berrocal AM, Flynn HW Jr.

Retina. 2009 Sep;29(8):1067-73.PMID: 19696701 [PubMed - indexed for MEDLINE]Related articles